Indoco Remedies Limited

NSE: INDOCO

26

total announcements

INDOCO.NS · 15 min delayed

Key Stats · Yahoo Finance · as of 21 Oct 2026

Market Cap

₹2,180 Cr

P/E (TTM)

739.1

P/E (Forward)

19.5

EPS (TTM)

₹0.32

52W Low

₹162.19

52W High

₹291.00

Dividend Yield

0.08%

Beta

0.62

Price / Book

2.1

Debt / Equity

116.9

Revenue (TTM)

₹1,873 Cr

Gross Margin

69.85%

Operating Margin

1.39%

NSEAppointmentMgmt Change28 Jul 2026

Indoco Remedies Limited

Appointment

Indoco Remedies Limited has informed the Exchange regarding the reappointment of Mrs ADITI PANANDIKAR as Managing Director of the company w.e.f. February 15, 2027, and the appointment of Mr. Sudhir Kadam as Senior Management Personnel.

Read more →📎 1 attachment
NSEOutcome of Board MeetingResults28 Jul 2026

Indoco Remedies Limited

Outcome of Board Meeting

Indoco Remedies Limited has announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, with revenue from operations at Rs. 40,897 lakhs and a net profit of Rs. 8,232 lakhs. The company has recognized a gain on sale of its Ophthalmic Business Division to Sunways (India) Private Limited as an exceptional item.

Read more →📎 1 attachment
NSEAnalysts/Institutional Investor Meet/Con. Call UpdatesResults17 Jul 2026

Indoco Remedies Limited

Analysts/Institutional Investor Meet/Con. Call Updates

Indoco Remedies Limited has scheduled an earnings conference call for Q1 FY2026-2027 on July 28, 2026, to discuss unaudited financial results for the quarter ended June 30, 2026.

Read more →📎 1 attachment
NSETrading WindowResults29 Jun 2026

Indoco Remedies Limited

Trading Window

Indoco Remedies Limited has informed the Exchange regarding the closure of the trading window due to the upcoming declaration of unaudited standalone and consolidated financial results for the quarter ended 30th June, 2026.

Read more →📎 1 attachment
NSEPress Release▲ PositiveRegulatory26 Jun 2026

Indoco Remedies Limited

Press Release

Indoco Remedies Limited has informed the Exchange regarding a press release dated Jun 26, 2026, titled "Indoco Remedies Goa Plant successfully clears Malta Medicines Authority audit". The company's manufacturing facility for solid oral dosage form (Plant I) located at Goa has received EU GMP certification from the Malta Medicines Authority confirming that it complies with the Good Manufacturing Practice requirements as referred in the EC Directive.

Read more →📎 1 attachment
← PreviousPage 2 of 2